A step toward defining optimal liposomal amphotericin B treatment duration in pulmonary mucormycosis: results from emulated trials. (PubMed, Antimicrob Agents Chemother) - Apr 29, 2026 - "Management of pulmonary mucormycosis includes intravenous liposomal amphotericin-B (L-AmB), followed by posaconazole or isavuconazole. Combination therapy did not improve prognosis. These results could inform randomized clinical trials assessing different first-line therapeutic strategies for pulmonary mucormycosis."
Clinical • Journal • Infectious Disease • Pulmonary Disease
|
|
Amandine Le Bourgeois; Anne Conrad; Anne Coste; Carine Halfon-Domenech; Christine Robin; Claire Defrance; Damien Dupont; David Boutoille; Dea Garcia-Hermoso; Fanny Lanternier; Felipe Suarez; Florence Ader; Florent Morio; François Danion; Françoise Botterel; Gaëlle Guillerm; Giovanna Melica; Jean-Etienne Herbrecht; Laurence Millon; Marie-Elisabeth Bougnoux; Marie-Pierre Ledoux; Olivier Lortholary; Olivier Paccoud; Raoul Herbrecht; Raphaël Porcher; Séverine Ansart; Solène Le Gal; Sophie Ducastelle-Leprêtre; Sylvain Poirée; Thomas Gastinne; Valérie Letscher-Bru
|